Research progress of dydrogesterone in the treatment of endometriosis.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing pharmacological mechanisms and clinical use without systematic methodology.
PubMed 38430648 · doi:10.1016/j.ejogrb.2024.02.034
What was done
This paper is a narrative review examining the biological mechanisms and clinical application of oral dydrogesterone for the treatment of endometriosis.
What was found
The abstract reports no numerical data, effect sizes, or statistical comparisons. Descriptively, dydrogesterone is reported to slow progesterone metabolism, inhibit angiogenesis and extracellular matrix degradation, induce ectopic endometrial atrophy via pro-apoptotic pathways, and downregulate inflammatory factors. Clinically, it is described as relieving symptoms, promoting fertility, being usable in combination regimens, and having a safe profile.
Why it matters
The review summarizes the mechanistic and therapeutic rationale for using dydrogesterone as an oral progestin option in endometriosis management.
Limits
No quantitative data, sample sizes, or search methodologies are reported in the abstract. As a narrative review, it lacks systematic evidence synthesis, risk-of-bias evaluation, and detailed comparative clinical efficacy or adverse event statistics.
Cited by
- supports Endometriosis implants grow in response to estrogen, and their growth slows down in response to progesterone.